Cargando…

First-generation BNT162b2 and AZD1222 vaccines protect from COVID-19 pneumonia during the Omicron variant emergence

OBJECTIVE: This study aimed to identify factors predicting pneumonia in adults with coronavirus disease 2019 (COVID-19) during the Omicron variant (B.1.1.529) emergence. We also evaluated, in fully vaccinated (BNT162b2 or AZD1222) individuals, if the time (<6 or ≥6 months) elapsed since the last...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murillo-Zamora, E., Trujillo, X., Huerta, M., Ríos-Silva, M., Lugo-Radillo, A., Baltazar-Rodríguez, L.M., Mendoza-Cano, O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Royal Society for Public Health. Published by Elsevier Ltd. 2022
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020510/ https://www.ncbi.nlm.nih.gov/pubmed/35594806 http://dx.doi.org/10.1016/j.puhe.2022.04.001

Ejemplares similares

COVID-19 Pneumonia in Fully Vaccinated Adults during the Dominance of the Omicron Sublineages BA.1.1 and BA.2 in Mexico
por: Murillo-Zamora, Efrén, et al.
Publicado: (2022)

Effectiveness of BNT162b2 COVID-19 Vaccine in Preventing Severe Symptomatic Infection among Healthcare Workers
por: Murillo-Zamora, Efrén, et al.
Publicado: (2021)

Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
por: Terpos, Evangelos, et al.
Publicado: (2022)

Reemerging Influenza Virus Infections during the Dominance of the Omicron SARS-CoV-2 Variant in Mexico
por: Ríos-Silva, Mónica, et al.
Publicado: (2022)

Decreased survival in children inpatients with COVID-19 and antibiotic prescription
por: Murillo-Zamora, Efrén, et al.
Publicado: (2022)

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection
por: Suah, Jing Lian, et al.
Publicado: (2022)

Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222
por: Perkmann, Thomas, et al.
Publicado: (2021)

A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222
por: Nantanee, Rapisa, et al.
Publicado: (2022)

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen
por: Baek, Yae Jee, et al.
Publicado: (2023)

Decreased risk of COVID-19 pneumonia in children and adolescents during the Delta variant emergence
por: Murillo-Zamora, E., et al.
Publicado: (2022)

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Adverse Events Associated with BNT162b2 and AZD1222 Vaccines in the Real World: Surveillance Report in a Single Italian Vaccine Center
por: Costantino, Maria, et al.
Publicado: (2022)

Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries
por: Dag Berild, Jacob, et al.
Publicado: (2022)

Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants
por: Niyomnaitham, Suvimol, et al.
Publicado: (2023)

Systemic reactogenicity following homologues and heterologous prime-boost AZD1222 and BNT162b2 COVID-19 vaccination of 2862 healthcare workers compared with an unvaccinated population
por: Tabatabaeifar, Sorosh, et al.
Publicado: (2023)

Durability of AZD1222 and hybrid humoral immunity against omicron BA.1 and BA.4
por: Soto-Rifo, Ricardo
Publicado: (2023)

AZD-1222: Guillain-Barre syndrome
Publicado: (2021)

AZD-1222: Rhabdomyolysis: case report
Publicado: (2022)

AZD-1222: Polyarthralgia: case report
Publicado: (2021)

Azd-1222: Myelitis: case report
Publicado: (2022)

Azd-1222: Thrombocytopenia: case report
Publicado: (2022)

Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production
por: Müller, Michael, et al.
Publicado: (2022)

Higher SARS-CoV-2 Spike Binding Antibody Levels and Neutralization Capacity 6 Months after Heterologous Vaccination with AZD1222 and BNT162b2
por: Müller-Hilke, Brigitte, et al.
Publicado: (2022)

Assessing the Relationship between Annual Surface Temperature Changes and the Burden of Dengue: Implications for Climate Change and Global Health Outcomes
por: Mendoza-Cano, Oliver, et al.
Publicado: (2023)

Acute Eosinophilic Pneumonia Associated With the Anti-COVID-19 Vaccine AZD1222
por: Miqdadi, Amal, et al.
Publicado: (2021)

AZD-1222: Nephrotic syndrome: case report
Publicado: (2021)

AZD-1222: Lack of efficacy: case report
Publicado: (2022)

AZD-1222: Immune thrombocytopenia: case report
Publicado: (2022)

AZD-1222: Leukocytoclastic vasculitis: case report
Publicado: (2022)

AZD-1222: Neck lymphadenitis: case report
Publicado: (2022)

AZD-1222: Immune thrombocytopenia: case report
Publicado: (2022)

Azd-1222: Immune thrombocytopaenia: case report
Publicado: (2022)

Azd-1222: Autoimmune encephalitis: case report
Publicado: (2022)

AZD-1222: Graves' disease: case report
Publicado: (2022)

AZD-1222: DRESS-syndrome: case report
Publicado: (2022)

AZD-1222: Thrombocytopenia and thrombosis: case report
Publicado: (2022)

AZD-1222: Urticarial vasculitis: case report
Publicado: (2022)

Azd-1222: Fulminant myocarditis: case report
Publicado: (2022)

AZD-1222: Lupus nephritis : case report
Publicado: (2022)

Azd-1222: Ventricular tachycardia: case report
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3d4l6intem9npc07t65p5uhd1k